DOP2005000050A - Métodos para tratar la esquizofrenia y/o las anomalías de glucorregulación - Google Patents
Métodos para tratar la esquizofrenia y/o las anomalías de glucorregulaciónInfo
- Publication number
- DOP2005000050A DOP2005000050A DO2005000050A DO2005000050A DOP2005000050A DO P2005000050 A DOP2005000050 A DO P2005000050A DO 2005000050 A DO2005000050 A DO 2005000050A DO 2005000050 A DO2005000050 A DO 2005000050A DO P2005000050 A DOP2005000050 A DO P2005000050A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- alkyl
- halogen
- hydrogen
- independently hydrogen
- glucorregulation
- Prior art date
Links
- 201000000980 schizophrenia Diseases 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- -1 benzyloxy, hydroxy Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona metodos para tratar la esquizofrenia y/o anomalies de glucorregulación en un paciente que lo necesite, que comprende administrar a dicho paciente una cantidad terapeuticamente eficaz de un compuesto de fórmula I en la que m es 0, 1 ó 2; n es 0, 1 ó 2; p es 0 ó1; cada R es independientemente hidrógeno, halógeno, trifluorometilo, alquilo C1-C6, alcoxi C1-C6, benciloxi, hidroxi, nitro o amino; cada R, es independientemente hidrógeno, alquilo C1-C6, alquenito C1-C6, alcanoilo C1-C6, halógeno, ciano, -C(O)-atquilo(C1-C6), -alquilen(C1,-C6)-CN, -alquilen(C,-C6)-NR'R" en el que R' y R" son cada uno independientemente hidrógeno o alquilo C1-C6, -alquilen(C1-C6)OC(O)-alquilo(C1-C6), o -CH(OH)R4 en el que R4 es hidrógeno o alquilo C1-C6; R2 es hidrógeno, alquilo C1-C6 opcionalmente sustituido con halógeno, hidroxi o benciloxi, alquenilo C1-C6, alquinilo C1-C6, -CO2-alquilo(C1-C6), o -R5-NR' R" en el que R5 es alquileno C1-C6, alquenileno C1-C6 o alquinileno C1-C6 y R' y R" son cada uno independientemente hidrógeno, alquilo C1-C6 o alternativamente el grupo -NR'R" como un solo grupo es 1-pirrolidinilo; y R3 es hidrógeno, nitro, amino, halógeno, alcoxi C1-C6, hidroxi o alquilo C1-C6. o una de sus sales farmaceuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55845104P | 2004-04-01 | 2004-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2005000050A true DOP2005000050A (es) | 2005-11-30 |
Family
ID=34978926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2005000050A DOP2005000050A (es) | 2004-04-01 | 2005-03-30 | Métodos para tratar la esquizofrenia y/o las anomalías de glucorregulación |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20070129403A1 (es) |
| EP (2) | EP2138176A1 (es) |
| JP (1) | JP2007531730A (es) |
| KR (1) | KR20070010161A (es) |
| CN (1) | CN1946399A (es) |
| AR (1) | AR048197A1 (es) |
| AT (1) | ATE446754T1 (es) |
| AU (1) | AU2005231446A1 (es) |
| BR (1) | BRPI0509512A (es) |
| CA (1) | CA2561162A1 (es) |
| CL (1) | CL2009001605A1 (es) |
| CY (1) | CY1109734T1 (es) |
| DE (1) | DE602005017373D1 (es) |
| DK (1) | DK1734959T3 (es) |
| DO (1) | DOP2005000050A (es) |
| ES (1) | ES2334241T3 (es) |
| GT (1) | GT200500063A (es) |
| IL (1) | IL178168A0 (es) |
| MX (1) | MXPA06011222A (es) |
| PA (1) | PA8628601A1 (es) |
| PL (1) | PL1734959T3 (es) |
| PT (1) | PT1734959E (es) |
| SI (1) | SI1734959T1 (es) |
| SV (1) | SV2006002069A (es) |
| TW (1) | TW200602040A (es) |
| WO (1) | WO2005097122A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| AR056968A1 (es) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
| TW200825091A (en) * | 2006-10-12 | 2008-06-16 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds useful in treating sodium channel-mediated diseases or conditions |
| EP2073806B1 (en) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| WO2010045197A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| PL2350090T3 (pl) | 2008-10-17 | 2015-11-30 | Xenon Pharmaceuticals Inc | Związki spiro-oksindolowe i ich zastosowanie jako środków terapeutycznych |
| US20100152249A1 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of The Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| WO2010141712A2 (en) * | 2009-06-03 | 2010-12-09 | Marquette University | Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| MY165579A (en) | 2009-10-14 | 2018-04-05 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| CN102946859B (zh) | 2010-02-26 | 2016-03-02 | 泽农医药公司 | 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途 |
| CN103512972A (zh) * | 2013-07-29 | 2014-01-15 | 上海交通大学 | 精神分裂症的生物标志物及其使用方法和应用 |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| KR101759122B1 (ko) | 2015-08-07 | 2017-07-18 | 계명대학교 산학협력단 | 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물 |
| CA3035092C (en) | 2016-08-24 | 2022-05-31 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating functional decline |
| JP7570345B2 (ja) * | 2019-03-19 | 2024-10-21 | ケンブリッジ コグニション リミテッド | 精神障害のための治療の診断および推奨の方法および利用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
| US4970218A (en) | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
| ES2065324T3 (es) * | 1987-04-24 | 1995-02-16 | Hoechst Roussel Pharma | N-(piridinil)-1h-indol-1-aminas, un procedimiento para su preparacion y su uso como medicamentos. |
| US5102891A (en) * | 1990-07-23 | 1992-04-07 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| US5356910A (en) * | 1993-07-19 | 1994-10-18 | Hoechst-Roussel Pharmaceuticals Inc. | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder |
| JP4189029B2 (ja) * | 1995-07-27 | 2008-12-03 | アベンティス・ファーマスーティカルズ・インコーポレイテッド | 抗けいれん剤としての未置換および置換ｎ−（ピロール−１−イル）ピリジンアミンの使用 |
| WO1997026265A1 (en) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| DE69737479D1 (de) | 1996-08-30 | 2007-04-26 | Novo Nordisk As | Glp-1 derivate |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| BR9810592A (pt) | 1997-07-16 | 2000-09-12 | Novo Nordisk As | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2005
- 2005-03-22 GT GT200500063A patent/GT200500063A/es unknown
- 2005-03-30 DO DO2005000050A patent/DOP2005000050A/es unknown
- 2005-03-31 AR ARP050101275A patent/AR048197A1/es not_active Application Discontinuation
- 2005-04-01 EP EP09012248A patent/EP2138176A1/en not_active Withdrawn
- 2005-04-01 JP JP2007506313A patent/JP2007531730A/ja not_active Abandoned
- 2005-04-01 TW TW094110410A patent/TW200602040A/zh unknown
- 2005-04-01 AU AU2005231446A patent/AU2005231446A1/en not_active Abandoned
- 2005-04-01 SV SV2005002069A patent/SV2006002069A/es unknown
- 2005-04-01 DK DK05732721.5T patent/DK1734959T3/da active
- 2005-04-01 WO PCT/US2005/011107 patent/WO2005097122A2/en active Application Filing
- 2005-04-01 KR KR1020067022972A patent/KR20070010161A/ko not_active Ceased
- 2005-04-01 CN CNA2005800121147A patent/CN1946399A/zh active Pending
- 2005-04-01 DE DE602005017373T patent/DE602005017373D1/de not_active Expired - Lifetime
- 2005-04-01 BR BRPI0509512-3A patent/BRPI0509512A/pt not_active IP Right Cessation
- 2005-04-01 MX MXPA06011222A patent/MXPA06011222A/es active IP Right Grant
- 2005-04-01 SI SI200530883T patent/SI1734959T1/sl unknown
- 2005-04-01 AT AT05732721T patent/ATE446754T1/de not_active IP Right Cessation
- 2005-04-01 PA PA20058628601A patent/PA8628601A1/es unknown
- 2005-04-01 PT PT05732721T patent/PT1734959E/pt unknown
- 2005-04-01 EP EP05732721A patent/EP1734959B1/en not_active Expired - Lifetime
- 2005-04-01 PL PL05732721T patent/PL1734959T3/pl unknown
- 2005-04-01 CA CA002561162A patent/CA2561162A1/en not_active Abandoned
- 2005-04-01 ES ES05732721T patent/ES2334241T3/es not_active Expired - Lifetime
-
2006
- 2006-09-18 IL IL178168A patent/IL178168A0/en unknown
- 2006-09-29 US US11/536,808 patent/US20070129403A1/en not_active Abandoned
-
2009
- 2009-07-17 CL CL2009001605A patent/CL2009001605A1/es unknown
-
2010
- 2010-01-11 CY CY20101100028T patent/CY1109734T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1946399A (zh) | 2007-04-11 |
| DK1734959T3 (da) | 2010-03-08 |
| WO2005097122A3 (en) | 2006-02-02 |
| PL1734959T3 (pl) | 2010-03-31 |
| DE602005017373D1 (de) | 2009-12-10 |
| WO2005097122A2 (en) | 2005-10-20 |
| MXPA06011222A (es) | 2007-01-16 |
| PA8628601A1 (es) | 2006-05-16 |
| AU2005231446A1 (en) | 2005-10-20 |
| BRPI0509512A (pt) | 2007-09-11 |
| AR048197A1 (es) | 2006-04-05 |
| CL2009001605A1 (es) | 2009-11-27 |
| JP2007531730A (ja) | 2007-11-08 |
| KR20070010161A (ko) | 2007-01-22 |
| SV2006002069A (es) | 2006-05-24 |
| CA2561162A1 (en) | 2005-10-20 |
| US20070129403A1 (en) | 2007-06-07 |
| TW200602040A (en) | 2006-01-16 |
| SI1734959T1 (sl) | 2010-02-26 |
| EP1734959B1 (en) | 2009-10-28 |
| ES2334241T3 (es) | 2010-03-08 |
| IL178168A0 (en) | 2006-12-31 |
| PT1734959E (pt) | 2009-12-24 |
| GT200500063A (es) | 2005-10-14 |
| EP2138176A1 (en) | 2009-12-30 |
| CY1109734T1 (el) | 2014-09-10 |
| ATE446754T1 (de) | 2009-11-15 |
| EP1734959A2 (en) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2005000050A (es) | Métodos para tratar la esquizofrenia y/o las anomalías de glucorregulación | |
| UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
| UY28374A1 (es) | Agentes terapéuticos | |
| PE20081493A1 (es) | Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso | |
| UY28144A1 (es) | Agentes terapéuticos | |
| CR8531A (es) | Compuestos y procedimientos para su uso | |
| UY28752A1 (es) | Agentes terapeuticos | |
| MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
| UY28369A1 (es) | Agentes terapéuticos | |
| AR063706A1 (es) | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. | |
| UY28376A1 (es) | Agentes terapéuticos | |
| ECSP088225A (es) | 1h-imidazopiridinas sustituidas con hidroxi y procedimientos | |
| DOP2005000071A (es) | "compuestos de metil-aril o heteroaril-amida sustituida" | |
| UY27872A1 (es) | Inhibidores de caspasa y usos de los mismos. | |
| MX2019014982A (es) | Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos. | |
| DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR061066A1 (es) | Coterapeutica para el tratamiento de epilepsia y trastornos relacionados | |
| EA200900048A1 (ru) | Новые карбонилированные (аза)циклогексаны в качестве лигандов d3 рецептора дофамина | |
| CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| MA32108B1 (fr) | Derives d'indazole | |
| MA30703B1 (fr) | Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii. | |
| CO5390085A1 (es) | Metodo para tratar enfermedades o condiciones desmielinizantes | |
| UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
| UY28377A1 (es) | Agentes terapeuticos |